Description: |
This trial measures PSA response in patients after definitive local therapy for prostate cancer who are non-metastaic but are experiencing a rising PSA and who have a PSA doubling time less than 12 months. Additional eligibility criteria include baseline PSA between 2-50 ng/ml and must be hormone-sensitive (testosterone > 150 ng/dL). Prior neoadjuvant and/or adjuvant therapy is acceptable. |
Link: |
|
Site: |
Johns Hopkins Hospital |
Principal Investigator: |
Emmanuel Antonarakis, M.D. |